Cargando…

Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats

BACKGROUND: Alzheimer’s disease (AD) is considered to be a neurodegenerative disorder that is characterized by increased oxidative stress. Medicinal plants, with their antioxidant properties, have been used to cure several human diseases. The aim of the current study was to explore the protective an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Li, Tan, Sha, Shan, Yi-long, Wang, Yu-ge, Cai, Wei, Huang, Xue-hong, Liao, Xi-yuan, Li, Hai-yan, Zhang, Lei, Zhang, Bing-jun, Lu, Zheng-qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5158169/
https://www.ncbi.nlm.nih.gov/pubmed/28003750
http://dx.doi.org/10.2147/NDT.S117469
_version_ 1782481573533188096
author Zhou, Li
Tan, Sha
Shan, Yi-long
Wang, Yu-ge
Cai, Wei
Huang, Xue-hong
Liao, Xi-yuan
Li, Hai-yan
Zhang, Lei
Zhang, Bing-jun
Lu, Zheng-qi
author_facet Zhou, Li
Tan, Sha
Shan, Yi-long
Wang, Yu-ge
Cai, Wei
Huang, Xue-hong
Liao, Xi-yuan
Li, Hai-yan
Zhang, Lei
Zhang, Bing-jun
Lu, Zheng-qi
author_sort Zhou, Li
collection PubMed
description BACKGROUND: Alzheimer’s disease (AD) is considered to be a neurodegenerative disorder that is characterized by increased oxidative stress. Medicinal plants, with their antioxidant properties, have been used to cure several human diseases. The aim of the current study was to explore the protective and therapeutic effect of baicalein on AD-induced rats. MATERIALS AND METHODS: Swiss Wistar rats were used in the study. The rats were divided into five groups. Group I: normal control group treated with water; Group II: disease control treated with AlCl(3) to induce the mimicking AD for 4 successive weeks (SW); Group III: normal control group treated with baicalein (5 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group IV: normal control group treated with baicalein (10 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group V: normal control group treated with rivastigmine (0.3 mg/kg) for 2 SW followed by combination of rivastigmine and AlCl(3) for 4 SW. Moreover, the therapeutic groups are as follows: Group VI: AD disease control treated with AlCl(3) for 4 SW and serving as the therapeutic positive group; Group VII: AD disease control + baicalein (5 mg/kg) for 12 SW; Group VIII: AD disease control + baicalein (10 mg/kg) for 12 SW; Group IX: AD disease control + rivastigmine (0.3 mg/kg) for 12 SW. Behavioral test, T-maze, and rotarod test were also performed before and after the treatment. At the end of the experimental study, all the rats were sacrificed and their brains were removed and divided into two portions. The first portion was homogenated for estimating the level of acetylcholinesterase (AchE) and acetylcholine (Ach). Another portion was used for histopathological evaluation. RESULTS: The current investigation showed that baicalein significantly reduced the duration of revolving on the rotarod, cage activity, and T-maze activity in a dose-dependent manner compared with the AD control group rats. It also altered the AchE and Ach levels in the brain homogenates. The histopathology study also provides strength to the protective effect of baicalein. CONCLUSION: The current study showed that baicalein significantly (P<0.05) improved the biochemical and histopathological condition of AD in rats.
format Online
Article
Text
id pubmed-5158169
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51581692016-12-21 Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats Zhou, Li Tan, Sha Shan, Yi-long Wang, Yu-ge Cai, Wei Huang, Xue-hong Liao, Xi-yuan Li, Hai-yan Zhang, Lei Zhang, Bing-jun Lu, Zheng-qi Neuropsychiatr Dis Treat Original Research BACKGROUND: Alzheimer’s disease (AD) is considered to be a neurodegenerative disorder that is characterized by increased oxidative stress. Medicinal plants, with their antioxidant properties, have been used to cure several human diseases. The aim of the current study was to explore the protective and therapeutic effect of baicalein on AD-induced rats. MATERIALS AND METHODS: Swiss Wistar rats were used in the study. The rats were divided into five groups. Group I: normal control group treated with water; Group II: disease control treated with AlCl(3) to induce the mimicking AD for 4 successive weeks (SW); Group III: normal control group treated with baicalein (5 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group IV: normal control group treated with baicalein (10 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group V: normal control group treated with rivastigmine (0.3 mg/kg) for 2 SW followed by combination of rivastigmine and AlCl(3) for 4 SW. Moreover, the therapeutic groups are as follows: Group VI: AD disease control treated with AlCl(3) for 4 SW and serving as the therapeutic positive group; Group VII: AD disease control + baicalein (5 mg/kg) for 12 SW; Group VIII: AD disease control + baicalein (10 mg/kg) for 12 SW; Group IX: AD disease control + rivastigmine (0.3 mg/kg) for 12 SW. Behavioral test, T-maze, and rotarod test were also performed before and after the treatment. At the end of the experimental study, all the rats were sacrificed and their brains were removed and divided into two portions. The first portion was homogenated for estimating the level of acetylcholinesterase (AchE) and acetylcholine (Ach). Another portion was used for histopathological evaluation. RESULTS: The current investigation showed that baicalein significantly reduced the duration of revolving on the rotarod, cage activity, and T-maze activity in a dose-dependent manner compared with the AD control group rats. It also altered the AchE and Ach levels in the brain homogenates. The histopathology study also provides strength to the protective effect of baicalein. CONCLUSION: The current study showed that baicalein significantly (P<0.05) improved the biochemical and histopathological condition of AD in rats. Dove Medical Press 2016-12-09 /pmc/articles/PMC5158169/ /pubmed/28003750 http://dx.doi.org/10.2147/NDT.S117469 Text en © 2016 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhou, Li
Tan, Sha
Shan, Yi-long
Wang, Yu-ge
Cai, Wei
Huang, Xue-hong
Liao, Xi-yuan
Li, Hai-yan
Zhang, Lei
Zhang, Bing-jun
Lu, Zheng-qi
Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
title Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
title_full Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
title_fullStr Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
title_full_unstemmed Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
title_short Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
title_sort baicalein improves behavioral dysfunction induced by alzheimer’s disease in rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5158169/
https://www.ncbi.nlm.nih.gov/pubmed/28003750
http://dx.doi.org/10.2147/NDT.S117469
work_keys_str_mv AT zhouli baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT tansha baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT shanyilong baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT wangyuge baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT caiwei baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT huangxuehong baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT liaoxiyuan baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT lihaiyan baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT zhanglei baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT zhangbingjun baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats
AT luzhengqi baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats